DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares
There isn't enough reported data to score DMAA yet.
DMAA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| N/A | |
| N/A |
There isn't enough reported data to rate DMAA's fundamentals.
DMAA PE Valuation
DMAA has no meaningful PE right now: it lost money over the past year.
DMAA Forward outlook
There aren't enough analyst estimates for DMAA to show an outlook.
DMAA Earnings Per Share
DMAA Quarterly Revenue
DMAA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$244.6K | -$138K |
| Q1 2026 | -$91.3K | +$160K |
| Q4 2025 | -$125.2K | -$125.1K |
| Q3 2025 | -$56.1K | +$1.1K |
| Q2 2025 | -$106.7K | -$106.5K |
DMAA's free cash flow was −$517,145 over the past year, against −$415,252 the year before. Free cash flow isn't a meaningful measure for financial services companies like DMAA.
DMAA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -28% | -9.2M shares |
DMAA has 24M diluted shares, down 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
DMAA Net Leverage
DMAA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 86.1 | Overbought |
| Stochastic | 98.5 | Overbought |
DMAA's weekly RSI is 86 (overbought) and its Stochastic is 98 (overbought).
DMAA PE vs Financial Services Sector
DMAA has no meaningful PE right now: it lost money over the past year.
DMAA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 0.2% above |
| 20 week MA | $10.8 | 1% above |
| 50 week MA | $10.6 | 2.7% above |
DMAA is in an uptrend: it's above all three of its weekly moving averages, and 2.7% above its 50-week average.
DMAA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $9.97 | $10.4 | +4% |
| 2026 YTD | $10.4 | $10.9 | +5.1% |
DMAA has finished every year since 2025 higher, and it's up 5.1% so far in 2026.